ParkinsonJ., 1817, An Essay on the Shaking Palsy, 1955, McMillan, London.
2.
CotziasG.C.Van WoertM.H., and SchifferL.M., Aromatic amino acids and modification of Parkinsonism, New Eng. J. Med., 276:374–379, 1967.
3.
CotziasG.C.PapavasiliouP.S., and GelleneR., Modification of parkinsonism—Chronic Treatment with L-Dopa, New Eng. J. Med., 280, 1969.
4.
BarbeauA., and RoyM., Six year results of treatment with L-Dopa plus Benzerazide in Parkinson's disease. Neurology, 26:399–404, 1976.
5.
HermanM.N.RowanA.J., and GoldensohnE.S., Changes in the human electroencephalogram during L-Dopa Treatment, Paper presented at American Neurological Association, 96th annual meeting, Washington, D.C., June 14–16, 1971, Program Abstr. No. 25, p. 78.
6.
McPhersonA., Convulsive seizures and electroencephalogram changes in three patients during Levodopa therapy, Neurology, 20:41–45, 1970.
7.
PikelnyR.T., The influence of L-dopa on the EEG in parkinsonism, Neurology, 21:453, 1971.
8.
GreenburgJ., Side effects of L-Dopa treatment, PA. Med., 74:55–56, 1971.
9.
SelbyG., Levodopa in Parkinson's disease-Australian collaborative trial, Med. J. Aust., 1:577–585, 1973.
10.
LunzerM.JamesI.M.WeinmanJ., and SherlockS., Treatment of chronic hepatic encephalopathy with Levodopa, GUT, 15:555–561, 1974.
11.
MarjerrisonG.BoultonA.A., and RajputA.H., EEG and urinary non-catecholic amine changes during L-Dopa therapy of Parkinson's disease, Dis. Nerv. Syst., 33:164–169, 1972.
12.
HicksE.P., and RischbiethB. H. C., An outpatient programme for L-Dopa therapy in Parkinson's disease, Med. J. Aust., 2:701–706, 1971.
13.
Green, and HaycookM., Electroencephalographic changes in parkinsonism patients treated with Levodopa and Levodopa-Amantadine in combination, Clin. Electroenceph., 2:28–34, 1971.
14.
RajputA.H. and RozdilskyB., Parkinsonism and dementia: Effects of Levodopa, Lancet1(7915): 1084, May 10, 1975 (in Letters to the Editor).
15.
RudkowskaA., and MisztalS., WPLYW L-Dopa NA ZAPIS EEG U OSOB DOTNIETYCH CHOROBA Parkinsona (The effect of L-Dopa on EEG tracings in patients with parkinsonism), POL. TYG. LEK.30:593–595, 1975.
16.
BengesserG., Vergleigh Zwischen EEG-Befund und Klinischem BILD BEI Parkinson-Patienten under L-Dopa (Comparison of EEG findings and clinical picture in Parkinson patients treated with L-Dopa), Wien. Med. Wochenschr., 125:120–121, 1975.
17.
MenaI.CourtJ.FuenzalidaS.PapavasiliouP.S., and CotziasG.C., Modification of chronic manganese poisoning: Treatment with L-Dopa or 5-OH Tryptophane, N. Engl. J. Med., 181:5–10, 1970.
18.
NewmanS.E.TuckerR.P., and KooiK.A., Lack of Levodopa effect on pre-existing temporal lobe focus, Arch. Neurol., Chicago, 29:122–123, 1973.
ParkesJ.D.SharpstoneP., and WilliamsR., Levodopa in Hepatic Coma, Lancet, 2:1341–1343, 1970.
21.
SarrazinA.EmeritJ.OliverL.RebeloF., and BousquetO., Traitement du coma hepatique par la L-Dopa: Premiers resultats Treatment of hepatic coma with L-Dopa: Preliminary findings), Presse Med., 79:2226–2227, 1971.
22.
LunzerM.JamesI.M., and SherlockS., Treatment of chronic hepatic encephalopathy with Levodopa digestion, 6:291, 1972.
23.
LanzingerG., and KommerellB., Levodopa-Therapie Beim Hepatischen Koma/Unter Desonderer Berucksightingung des EEG-Verlaufs/(Levodopa treatment in hepatic coma/with special consideration of serial EEG changes), Deut. Med. Wochenschr., 99:700–705, 1974.